Cogent: Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline

 Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations

In vivo characterization shows a novel, selective, reversible FGFR2 inhibitor has potency against molecular brake mutations and potential advantages over covalent approaches

APEX Part 2 underway in AdvSM patients at once-daily 150 mg optimized dose of bezuclastinib

https://www.biospace.com/article/releases/cogent-biosciences-presents-preclinical-data-at-aacr-annual-meeting-highlighting-precision-therapy-pipeline-and-announces-initiation-of-part-2-of-the-registration-enabling-apex-trial-with-bezuclastinib-in-advanced-systemic-mastocytosis/